Verrica Pharmaceuticals Inc (VRCA NASDAQ) stock market data APIs
$5.2943
0.02(0.4%)
as of September 4, 2026
Try our APIs with
free plan!
Verrica Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Prev. Close
5.2943
Open
5.2949
High
5.5366
Low
5.2583
52 wk Range
3.28-9.8212
Market Cap
91 048 K
Shares Outstanding
17 179 K
Revenue
30 321 K
EPS
-0.54
Beta
1.495
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Verrica Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verrica Pharmaceuticals Inc data using free add-ons & libraries
Get Verrica Pharmaceuticals Inc Fundamental Data
Verrica Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 30 321 K
- EBITDA: -25 964 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Verrica Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.47
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verrica Pharmaceuticals Inc News
New
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Verrica Pharmaceuticals Inc. WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medic...
Verrica (VRCA) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jayson RiegerChief Medical Officer - Noah RosenbergInterim Chie...
Verrica Pharmaceuticals Q2 Earnings Call Highlights
Key Points Interested in Verrica Pharmaceuticals Inc.? Here are five stocks we like better. YCANTH sales accelerated: U.S. net product revenue rose 18.7% sequentially to $5.1 million, while dispensed...
Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts
(RTTNews) - Verrica Pharmaceuticals Inc. (VRCA), a therapeutics company, on Monday announced the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH in treating common warts. Addit...
Get Verrica Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
